Four Under the Radar Biotechnology Stocks that Could Rally this Week
An excerpt from .....
Four Under the Radar Biotechnology Stocks that Could Rally this Week: ONCS, OMER, KERX, NBS
Posted 11 Nov 2012
By Sven Olson
Omeros Corporation (NASDAQ:OMER) fell by 13% last week in preparation of the company’s data for its first pivotal Phase III clinical trial evaluating OMS302 at the American Academy of Ophthalmology (AAO) Annual Meeting. OMS302 is designed to maintain intraoperative mydriasis (pupil dilation) and reduce postoperative pain and irritation resulting from cataract and other lens replacement surgery. Obviously, investors are not expecting much from the company’s trial later this week, but it may provide a pleasant surprise.
Up until June, Omeros was one of the best performing stocks in the market, with a gain of more than 230%. Yet despite the fact that it’s still trading with a 110% YTD gain, the stock has lost a significant amount of its momentum following a public offering. In addition, the company is also dealing with a messy settlement with its former CFO, which has scared some investors. However, with all these problems, it is possible that data could become a bright spot. The company’s initial rally in 2012 was due to OMS302 achieving both Primary and Secondary endpoints in its Phase III trial, therefore we already know the product is effective to some degree. With that being said, I am not sure what we will learn when the company announces data at the AAO, but it could be enough to excite investors and produce gains.